Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemia

8 Jul 2023

Abstract excerpt

Despite the approval of several drugs for AML, cytarabine is still widely used as a therapeutic approach. However, 85% of patients show resistance and only 10% overcome the disease. Using RNA-seq and phosphoproteomics, we show that RNA splicing and serine-arginine-rich (SR) proteins phosphorylation were altered during cytarabine resistance. Moreover, phosphorylation of SR proteins at diagnosis were significantly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to RNA modifications and cancer
Share to RNA Research and Splicing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37422594
DOI: 10.1038/s41375-023-01963-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemiaPMID 37422594Read ↗

The ribosomal protein S6 kinase alpha-1 (RPS6KA1) induces resistance to venetoclax/azacitidine in acute myeloid leukemiaSemantic proximity Read ↗

Sequence-dependent splicing dysregulation drives therapy resistance in pediatric AML.Semantic proximity Read ↗

Genome-wide investigation of differentially expressed alternative splicing and RNA-binding protein genes association with AML drug resistanceSemantic proximity Read ↗

Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax.Semantic proximity Read ↗

Aberrant splicing and drug resistance in AMLSemantic proximity Read ↗

ASAH1-mediated sphingolipid metabolic reprogramming in venetoclax resistance of AML: beyond the monocytic phenotypes.Semantic proximity Read ↗

The Class IIA Histone Deacetylase (HDAC) Inhibitor TMP269 Downregulates Ribosomal Proteins and Has Anti-Proliferative and Pro-Apoptotic Effects on AML CellsSemantic proximity Read ↗

Evolution of transcriptomic profiles in relapsed inv(16) acute myeloid leukemia.Semantic proximity Read ↗

SRSF2 mutations drive daunorubicin resistance in acute myeloid leukemia via THBS1 stabilization.Semantic proximity Read ↗

Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid LeukemiaSemantic proximity Read ↗

Venetoclax combined with hypomethylating agents and the CAG regimen (DCAG) in relapsed/refractory AML: A single- center clinical trialSemantic proximity Read ↗

The RNA N⁶-Methyladenosine Methylome Coordinates Long Non-Coding RNAs to Mediate Cancer Drug Resistance by Activating PI3K SignalingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.